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Summary
New ligands for a variety of biological targets can be
selected from biological or synthetic combinatorial
peptide libraries. The use of different libraries to se-
lect novel peptides with potential therapeutic applica-
tions is reviewed. The possible combination of molec-
ular diversity provided by combinatorial libraries and
a rational approach derived from computational mod-
eling is also considered. Advantages and disadvan-
tages of different approaches are compared. Possible
strategies to bypass loss of peptide bioactivity in the
transition from ligand selection to in vivo use are dis-
cussed.
Introduction
Combination of a relatively small number of amino
acids is the strategy used by nature to construct pro-
teins, which are the most variable and adaptable mole-
cules of life. No other molecule can be organized in
such a large number of different structures and carry
out so many different functions as proteins. Proteins
are the principal mediators of molecular “crosstalking.”
Their extreme variability makes them suitable media-
tors of specific molecular interactions. Interactions be-
tween proteins, or between proteins and other mole-
cules, mediate all the physiological and pathological
phenomena of life and as such can be the targets of
specific drugs to modify physiological or pathological
events.
Evolution of chemical and “biological” technologies,
for the production of peptides and proteins in the labo-
ratory, has made it possible to use the same natural
molecular approach to construct “new” peptide se-
quences, which recognize specific targets. The intrinsic
variability of peptide sequences and their ability to
specifically recognize other molecules can therefore be
used to design peptide drugs.
The principle for selecting of new ligands for a variety
of biological targets by means of combinatorial peptide
libraries exploits the natural diversity of protein-protein
and protein-ligand interactions. Different combinatorial
approaches have been applied since the mid-’80s to
generate molecular diversity through synthetic or phage-
display libraries [1–3] of many different peptide se-
quences that can be used to select lead bioactive com-
pounds for drug discovery and basic research.
Multiple peptide synthesis techniques provide the*Correspondence: braccil@unisi.itbasis for the synthetic combinatorial library approach.
The optimization of chemistry and the automation and
miniaturization of solid-phase peptide synthesis ena-
bled peptide libraries to be built using different solid
supports, such as resin beads [1], pins [4], glass chips
[5], tea bags [6], and cellulose membranes [7]. Peptide
libraries can be used to “fish” active ligands from a
large variety of structural combinations, making it pos-
sible to identify peptide mimotopes [8], which mimic
the structure and function of a native protein. Peptide
mimotopes, with a sequence generally different from
that of native epitopes, can mimic antigen-antibody
and protein-ligand binding sites in general.
Synthetic combinatorial peptide libraries have been
used successfully to identify bioactive peptides, includ-
ing antimicrobial peptides [9], opioid receptor antago-
nists [10], ligands for cell surface receptors [11], protein
kinase inhibitors and substrates [12, 13], T cell epitopes
[14, 15], peptides binding to MHC molecules [16], and
peptide mimotopes of receptor binding sites [17].
Libraries of peptides displayed on biological sur-
faces, such as bacteriophage particles, have become a
widely studied laboratory procedure for the identifica-
tion of specific ligand molecules in research and drug
discovery. The technology is based on an in vitro selec-
tion procedure in which a peptide gene is genetically
fused to a bacteriophage coat protein, resulting in dis-
play of the peptide on the surface of the viral particle.
From the mid-’80s, when the first phage peptide library
was constructed, random peptide libraries displayed
on phages have been used for a variety of biological
and biotechnological applications, including ligands to
target receptors [18, 19], specific ligands for DNA se-
quences [20], enzyme inhibitors [21, 22], peptides that
mimic carbohydrate structures [23], protein-protein in-
terfaces [24–28], and receptor binding sites [29, 30].
Phage-display libraries have led to selection of pep-
tides against cancer cells [31–33] and against cancer-
associated proteins [34]. In vivo screening of phage-
display libraries has enabled identification of peptides
that target a specific organ or tissue [35, 36] and that
specifically bind to the endothelium of tumor blood
vessels [37–39] and lymphatic vessels [40].
The combinatorial peptide library approach is mainly
based on three methods. In one, peptide libraries are
synthesized and cleaved from a solid support to be
screened as free compounds [2]. In a second, synthetic
combinatorial libraries of peptides are assayed on their
solid support [1, 8]. The third method is based on phage
display, which enables selection of clones of interest
rather than screening, because large phage libraries
can be panned against a target molecule by standard
protocols (for reviews see [41] and [42]), allowing en-
richment of only a few hundred specific phages that
can easily be screened for positive ligands in a single
test. Specific phages are then treated for DNA se-
quencing and peptide genes are revealed for subse-
quent chemical synthesis.
The development of technologies enabling construc-
tion of combinatorial libraries of a huge number of dif-
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able methods for high throughput screening of active
ligands.
The above three technologies for selection of peptide
ligands fall into two groups: libraries that allow the se-
lection of ligands in their final unlabeled and soluble
form and those by which peptides are selected while
still linked to their “support,” either synthetic or biologi-
cal, or to a labeling molecule.
Here we review the use of different libraries to select
new peptides with potentially therapeutic applications.
The drawbacks and advantages of different approaches
are compared and we focus particularly on strategies
to bypass loss of peptide activity during the different
steps from ligand selection to in vivo use. We also look
at the possibility of combining molecular diversity pro-
vided by combinatorial libraries and a rational ap-
proach derived from computational modeling, during
different stages of novel peptide drug selection and op-
timization.
Generation of Molecular Diversity
Upgraded technologies for generating peptides by
chemical synthesis or molecular biology techniques are
generating an increasing number of different sequences.
The simultaneous development of bioinformatics and
computer modeling, plus the increasing availability of
three-dimensional molecular structures, have increased F
bthe power and reliability of rational molecular design.
TNew bioactive peptides can therefore be obtained by
generating libraries containing the highest possible
number of different sequences and then fishing for the
(desired function, or by rational design of an appropriate
Tstructure, hopefully with the desired function. These
c
two opposite approaches can now be combined at dif-
m
ferent steps of the selection procedure and the relative
a
contributions of rational and irrational selection depend
c
on available knowledge about protein and peptide d
structure-function and may change at different steps of t
the process. l
nSynthetic Combinatorial Libraries b
The first validation of the combinatorial approach was c
obtained using both synthetic [1, 2] and phage-display t
peptide libraries [43, 44] to identify B cell epitopes p
using well-defined monoclonal antibodies. The combi- p
natorial approach identified peptides having no sequence i
homology with the native antigen, when antibodies, re- w
ceptors, or other proteins that bind to conformational t
epitopes or active sites were used to screen the librar-
ies [45, 46]. c
The first use of synthetic peptide libraries was re- a
ported by Geysen and colleagues in 1984 [4], using the a
pin method, and since then many papers describing s
different methods of synthesizing and screening pep- X
tide libraries have been published. a
Synthetic combinatorial libraries, especially synthetic e
peptide libraries, are generally prepared by two dif- a
ferent methods, the “divide, couple and recombine” o
o(DCR) method [1, 2, 47], also known as “portion mixing”igure 1. Portion Mixing Method for Synthetic Combinatorial Li-
raries
he resin is divided and recombined at every coupling step.Figure 1), and the “amino acid mixture” method [48].
he DCR method involves dividing resin into pools,
oupling amino acids to individual aliquots of resin,
ixing them and dividing them again for next amino
cid coupling. This process generates “one-bead one-
ompound (OBOC)” libraries containing millions of ran-
om peptides [1], each bead expressing only one pep-
ide and each peptide having equal distribution in the
ibrary.
Up to 108 different peptides, which can be simulta-
eously selected for a given target, can be synthesized
y this technique, the main drawback being the identifi-
ation of the peptide sequence of the selected bioac-
ive bead. Microsequencing and mass spectrometry,
erformed directly on the beads, are possible ap-
roaches for peptide identification, together with chem-
cal encoding, a method based on tagged peptides in
hich the tag enables the peptide sequence to be re-
raced.
In order to bypass the need for peptide sequencing,
ombinatorial peptide libraries with both randomized
nd defined positions can be produced using the amino
cid mixture method. In mixture libraries, peptides are
equences of randomized (X) and defined (O) positions.
positions are obtained by coupling mixtures of amino
cids in a predetermined molar ratio in order to have
qual representation of each amino acid. Single defined
mino acids are inserted in O positions. Identification
f bioactive peptide sequences in mixture libraries is
btained by deconvolution.
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erative process [1, 2] and a positional scanning [49]
(Figure 2). In the first approach a progressive selection
is performed, choosing one amino acid at a time for
each position. Sublibraries are generated on the basis
of results of the previous one. In positional scanning all
sublibraries can be assayed at the same time, because
each variable position is tested independently of the
others. In the case of positional scanning, the sequence
is reconstructed at the end of the process, whereas in
the iterative process the sequence is obtained step by
step.
Deconvolution methods evaluate the contribution of
each residue at each sequence position to biological
activity. They can easily be used with arrays of peptide
mixtures obtained using different supports. In particu-
lar, spatially addressable parallel peptide libraries, such
as peptide libraries synthesized on solid support by
SPOT synthesis, pin technology and peptide microar-
ray, enable identification of the sequences of individual
bioactive peptides by the deconvolution process, since
each peptide mixture is well localized on the solid sup-
port. The large number of peptides that can be pro-
duced and screened simultaneously by this approach
enables synthesis of complex libraries [50].
Dynamic combinatorial libraries (Figure 3) are a re-
cent development of combinatorial chemistry [51].
Traditional combinatorial libraries consist of stable com-Figure 2. Descriptive Model of Iterative Pro-
cess and Positional Scanning Deconvolu-
tion Approaches
See text for details.Figure 3. Dynamic Libraries
See text for details.pounds, whereas dynamic combinatorial libraries are
based on reversible reactions that produce “dynamic
mixtures” in which reactants and products are present
in thermodynamic equilibrium. The biological target of
these mixtures selects the best binding structures and
shifts the equilibrium of the reaction by subtracting
the product.
Dynamic combinatorial libraries therefore do not
have a deconvolution step and ligands are selected di-
rectly in the reaction mixture. Although innovative and
promising, dynamic combinatorial libraries are so far
limited to a small number of reversible reactions and
libraries of moderate size.
In the “libraries from libraries” approach (Figure 4)
[52], combinatorial libraries of peptides are built on a
solid phase and are subsequently modified to maximize
diversity: oxidations, reductions, alkylations, and acyl-
ations are performed, multiplying the number of new
small organic compounds exponentially.
These second generation combinatorial libraries may
give rise to more stable active compounds, but usually
have different physical, chemical, and functional char-
acteristics [53] from the first generation.
Biological Libraries
Molecular biology techniques make it possible to build
polypeptide libraries expressed by different biologicalFigure 4. Example of Libraries from Libraries
See text for details.
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420wentities including bacteria [54], phages, and ribosomes
t[55]. Biological peptide libraries are mainly based on
aphage exposition with peptides displayed by fusion
swith a viral coat protein. Many phages are used for dis-
mplaying peptides [56, 57] but the most widely used is
mthe filamentous bacteriophage M13. Peptides dis-
played on M13 virus can be exposed on the phage sur-
sface fused to the amino terminus of pIII or pVIII surface
bproteins (Figure 5).
iPeptides fused to pIII usually give higher affinity li-
vgands than peptides fused to pVIII, mainly due to the
ehigh avidity produced by the great number of pVIII cop-
Sies (about 2700 copies, versus only 3–5 copies of pIII),
awhich results in strong binding, even for peptides with
low affinity.
lIn some cases, ligand affinity can also be predeter-
tmined (within a range) by modifying the stringency of
pselection protocols. Selections are usually performed
dusing purified target molecules, although direct pan-
aning on cells [58, 59] and in vivo panning [60] have
obeen described.
tTarget molecules (proteins, sugars, or fatty acids) are
hcoated onto tubes (immunotubes) under conditions
Osimilar to those employed in ELISA [28, 61–64]. Phage
clibraries are then allowed to bind to the tube and spe-
ncific ligands are eluted by pH change.
Low-density target coating and extensive washing of
the tube enrich for high-affinity binders; high-density S
Gimmunotube coating and less stringent washing pro-
cedures may otherwise be used to select low-affinity b
sligands. In some cases, the avidity of target molecule
binding, associated with the multivalent display of t
sbinders on phages, makes it difficult to distinguish be-
tween medium- and high-affinity clones in the selection p
pprocedure. Selection schemes making use of streptavi-
din-coated magnetic beads allow the reaction of bio-
ttinylated molecules with phages in solution, followed
by addition of streptavidin-coated beads. This de- m
lcreases avidity effects to a large extent and makes it
possible to dictate conditions for the selection of bind- l
lers with suitable kinetic constants. In this case, how-
ever, a subset of the isolated binders is directed against
dstreptavidin, rather than against the biotinylated anti-
gen. The problem is typically negligible for large target t
dmolecules, but may be serious for small biotinylated
molecules such as haptens. Recovery of binders to is
e
t
d
t
o
a
t
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Figure 5. Peptides Displayed on M13 Phage Surface as Fusion to u
the Amino Terminus of pVIII (A) or pIII (B) Coat Proteins o
Proportions are not observed in this picture. [
itreptavidin can be eliminated by panning in the pres-
nce of a soluble excess of the streptavidin, or alterna-
ively, by using target molecules biotinylated with biotin
isulfide N-hydroxysuccinimide ester. This enables elu-
ion of positive phage ligands by incubation with dithi-
threitol, which reduces the disulfide bridge between
ntigen and biotin, leaving the targeted protein bound
o the phage particle without impairing the subse-
uent infection.
Another effective system made possible by phage
isplay is selection by competition. Specific phage
inders may be detached from the “antigen” by means
f a competitor molecule, which binds the antigen nat-
rally. This method was tested by us for the production
f a nicotinic acetylcholine receptor scFv mimotope
65], but can be used for the general recovery of ligands
nterfering with binding of molecules, interaction of
hich triggers a pathological mechanism. An exhaus-
ive example of this system is described by Mourez et
l. [28] in which specific anti-anthrax toxin peptides are
elected by incubating a phage library with the target
olecule and eluting specific binders with competitive
olecules.
Identification of a specific peptide sequence from a
elected phage is possible because phage display li-
raries enable pairing of phenotype with genotype. This
s possible because the phage carries an expression
ector, termed phagemid, on which the peptide gene is
ncoded as a fusion gene with the viral coat protein.
equencing of the peptide gene insert enables the
mino acid sequence to be recognized.
The great advantage of phage libraries is the very
arge number of different peptide sequences (over 109)
hat can be displayed on viral surfaces. Moreover,
hage libraries display their ligands in multiple copies
ue to the multiplicity of coat proteins to which they
re fused. This, however, affects the binding capacity
f peptides mounted on a phage and, in some cases,
he corresponding synthesized monomeric peptide be-
aves differently when tested as a soluble molecule.
f course, only L-amino acid can be encoded and the
onstruction of phage peptide libraries containing non-
atural amino acids is not possible.
election of Active Compounds
iven the large number of different sequences that can
e generated in peptide libraries, high-throughput
creening is necessary to select novel peptides with
he desired biological activity. Binding or functional as-
ays can be used to screen synthetic or phage display
eptide libraries, using a biological target, such as a
rotein, an enzyme, or a whole cell.
In phage display, ligand selection is divided into the
wo distinct steps of panning and screening. This
akes it possible to combine the extremely high mo-
ecular diversity of these libraries with accessible bio-
ogical tests for binding or for biological activity of se-
ected clones.
SPOT synthesis of peptides on microarrays reveals
irect links between peptide activity and sequence. Al-
hough phage peptide libraries have a higher molecular
iversity, even compared to the most recent miniatur-
zation of SPOT synthesis, they still require gene se-
Review
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and time consuming. The one-bead-one-peptide ap-
proach allows direct identification of active beads;
however, an additional identification step of the active
ligand sequence displayed on the bead is required af-
ter screening.
In the binding assays, target-ligand interactions can
be detected by incubating immobilized peptide librar-
ies with the target, which can be visualized taking
advantage of suitable groups, such as enzymes, fluo-
rescent probes, dyes, radio nuclides, or biotin. The pep-
tide-bound target can be detected by colorimetric as-
says [66], fluorescent microscopy, or flow-cytometry [67].
Solid-phase-linked peptide libraries can also be
screened using whole cells or microorganisms, such as
a virus or bacterium and the cell-ligand interactions can
be visualized directly by microscope.
High-throughput functional assays of enzyme activity
have been used for the selection of substrates or inhibi-
tors of kinases by radionuclide-based screening [12, 13]
or by phage-display peptide phosphorylation [68] and
for the selection of substrates of proteolytic enzymes
by a fluorescence-quenching approach [69], using pep-
tides immobilized on different solid supports [70].
The major drawback shared by all peptide libraries,
in which selection of bioactive ligand is performed on
support-linked peptides, is that the activity of the se-
lected sequences, once these are synthesized as sol-
uble compounds, may be different from that of the
immobilized peptides. Moreover, the screening of sup-
port-linked synthetic libraries and phage display librar-
ies can be affected by multivalent binding and thus give
little information on the real affinity of the final soluble
peptides. On the other hand, when performing high-
throughput screening of free peptides in solution, auto-
mation, miniaturization, and very sensitive detection
methodologies are required. Different assays such as
ELISA, cell-based cytotoxic assay, antimicrobial assay,
affinity chromatography, radiometric and fluorescence-
based assays can be used.
ELISA screening of compounds is now using 384-
well microplates, or larger, handled automatically. In-
creased sensitivity of the fluorescence and radioactivity
detection technologies is therefore required as assay
volume decreases [71, 72].
New fluorescence-based detection methods have
been developed with improved sensitivity and selectiv-
ity. Examples of the most widely used are fluorescence
resonance energy transfer (FRET), fluorescence polar-
ization (FP), and fluorescence correlation spectroscopy
(FCS) [71]. FRET is based on energy transfer between
appropriate energy donor and acceptor molecules. It is
used in monitoring enzyme activity: typically, a short
peptide corresponding to the sequence for a natural
cleavage site of the enzyme is synthesized and labeled
at opposite ends with appropriate donor and quencher
molecules. Before cleavage, the donor and quencher
are very close and the effective fluorescence detected
is low; once the two parts drift apart the fluorescent
signal increases.
FP experiments allow measurement of changes in
the emitted light intensity of small labeled probes on
binding to larger molecules: the sample is excited with
polarized light and when a binding equilibrium is estab-lished, the observed polarization of the emitted light in-
creases.
FCS is an emerging detection technique for high-
throughput screening: measurements are carried out
using confocal optics to provide the highly focused ex-
citation light and background rejection required for
miniaturized samples. This technique is used to moni-
tor binding interactions as well as other molecular
events, since binding of a fluorescent probe to a mole-
cule results in a change in its effective light emission.
Mass spectrometry [73] and BIACORE [74] are pow-
erful techniques for screening soluble and unlabeled
peptides. Particularly, BIACORE allows real-time detec-
tion of soluble peptide binding not only to proteins but
to different biomolecules, like nucleic acids or sugars
and also to cell membranes or whole cells. Moreover,
the BIACORE allows the one-step measurement of ki-
netic rates and affinity of binding, thus providing an af-
finity ranking of functional peptides. This approach was
used by our group to select peptide mimotopes of the
nicotinic receptor ligand site [17, 75].
Combining Molecular Diversity with Rational Design
Structure-based molecular design and construction of
molecular diversity are not mutually exclusive, but can
be combined for the development of new specifically
targeted drugs. The availability of structure-function in-
formation on the molecular components of the targeted
biological reaction can be used for rational design of
bioactive peptides. A rational approach can be the first
step for generation of new bioactive peptides and can
be combined, from the beginning of the process, with
the molecular diversity offered by peptide libraries.
Structure-function information can be used to limit the
number of variables in a positional scanning library,
thus enabling synthesis of libraries composed of longer
peptides [17] or to design structurally constrained
chemical [76, 77] or biological [78] libraries. On the
other hand, multiple peptide synthesis can increase the
number of computational analysis-derived sequences
and structures to be tested as possible active com-
pounds. As a general rule, the rational approach can
help limit “randomness,” whereas generation of molec-
ular diversity can help extend the range of rational ap-
proaches.
The step in which combination of rational design and
generation of molecular diversity is generally most ef-
fective is the optimization of lead compounds. Optimi-
zation of the activity of a peptide lead compound in-
volves careful analysis of the correlation between
peptide sequence, and when possible active structure,
and activity, pinpointing critical positions and residues.
The most commonly used experimental techniques are
systematic residue replacement (such as alanine scan-
ning) and progressive deletion of peptide sequence.
Definition of peptide active three-dimensional structure
is obviously additional important information, which
may enable accompanying experimental information by
computer modeling. Once information has been gath-
ered on peptide functional constraints, subsequent
peptide libraries can be generated with the aim of ob-
taining second generation products with increased ac-
tivity. Even at this stage, a combination of rational ap-
Chemistry & Biology
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mratio between the two apparently opposite procedures
idepends first of all on availability of structure-function
sinformation on the peptide and its target. Amino acids
lnot critical for activity can be replaced with others, gen-
erally the 20 natural amino acids, but nonnatural amino
eacids can also be included. Alternatively, molecular
pmodeling can help reduce variability, giving indications
pabout more suitable replacements in noncritical or even
lcritical positions. Two alternative pathways for obtain-
uing high-affinity bioactive peptides using a combination
tof computer modeling and molecular diversity have
tbeen proposed [75, 79].
tRational optimization of lead peptides can include in-
ptroduction of structural constraints and generation of
cpeptides with higher affinity that are also more stable
oto biological degradation [79, 80].
pA combination of random selection, usually starting
ofrom phage display libraries, and further optimization of
mleads by rational design and/or chemical synthesis of
6molecular variants has been used for selection of bio-
factive products for a wide range of applications includ-
ting peptide inhibitors of β-lactamase [81], human
tP-selectin antagonists [82], α4β7 integrin antagonists
m[83], peptide antagonists of Grb2-SH2 domain [84], and
many others.
gPhage-derived lead peptides can be optimized by
tmutating the sequence of the original peptide by intro-
wducing DNA substitutions, insertions, and deletions to
tconstruct new phage display sublibraries that are then
wpanned against the target molecule. We cite two ex-
thaustive examples in which (1) alanine scanning muta-
mgenesis was performed by constructing new minilibra-
fries of mutated peptides displayed on a phage [85] and
t(2) improved mimetic properties of peptides was ob-
itained by generating new phage libraries, using 39-ran-
dom mutagenic oligonucleotides, by a procedure that
oresembles natural immune system affinity maturation [86].
aAn essentially similar combination of molecular diver-
gsity and rational design can be applied when the lead
ppeptide is a natural endogenous peptide, the functional
hproperties of which can be mimicked or inhibited by a
tnovel bioactive peptide. Important examples of strate-
gies that can be applied in such a case come from mim-
l
icry of enkephalins [87]. The recent discovery that
c
membrane receptors for several endogenous regula- b
tory peptides are reexpressed or overexpressed in cer- b
tain tumors has dramatically amplified research on t
novel bioactive peptides derived from natural sequences s
for tumor targeting and diagnosis [88]. d
a
Maintenance of Peptide Bioactivity from Selection s
to In Vivo Use w
A limitation of peptide combinatorial libraries is that se- m
lected biologically active ligands that are L-peptides l
are not suitable as potential therapeutic drugs, mainly M
due to their short half-life in vivo because of rapid pro- c
teolytic cleavage. Several strategies have been used to b
preserve peptide bioactivity in the transition from the l
peptide selection by synthetic or phage libraries to use
in vivo. c
They include introduction of D- [89] or unnatural t
tamino acids, introduction of structural constraints,yclization, or conversion of lead peptides into small
olecules [90] or into peptidomimetics [91] including
n this term either amide bond mimetics or nonpeptide
tructures that mimic the binding interactions of the re-
ated peptides.
Nonnatural amino acids libraries can be obtained
ither by coupling nonnatural amino acids in standard
eptide chemistry or by modifying all L-amino acid
eptides by N-alkylation or acylation to produce stable
inear or cyclized analogs. Structural constraints are
sually introduced to stabilize active conformers and
hen to enhance bioactivity of compounds. In addic-
ion, constraints have the advantage of stabilizing pep-
ides against proteolytic action. In constrained libraries,
eptide secondary structure is blocked in an “active
onformation.” For this purpose, libraries may be built
n constrained scaffolds in order to display, for exam-
le, a β-turn (Figure 6). Intramolecular cyclization is an-
ther way of preserving peptides in a particular confor-
ation, together with disulfide bond formation (Figure
). All these techniques have been successfully used
or identifying active ligands [92, 93]. The drawback of
hese approaches is that the biological activity of pep-
ides can be profoundly modified by such structural
odifications.
In previous studies we showed that the Multiple Anti-
en Peptide (MAP) [94, 95] dendrimeric forms of pep-
ide mimotopes of the nicotinic receptor binding site
ere strong antidotes for the neurotoxin α-bungaro-
oxin, whereas related monomeric peptide mimotopes
ere not effective in vivo, despite in vitro activity iden-
ical to the corresponding dendrimers [75, 96]. The re-
arkably higher in vivo efficiency of the dendrimeric
orm with respect to the monomeric peptide was due
o acquired resistance to protease and peptidase activ-
ty [97].
Our results, obtained comparing peptides of different
rigin and length, confirmed that the synthesis of bio-
ctive peptides in MAP dendrimeric form can be a
eneral method of imparting resistance to protease and
eptidase activity, resulting in a dramatically increased
alf-life. All the dendrimeric peptides we tested retained
he full biological activity of the native peptide [97].
Once produced as soluble compounds, peptides se-
ected by phage display or solid phase-linked libraries
an again present the problem of the maintenance of
iological activity. This problem can be circumvented
y synthesizing selected peptides in MAP form. Pep-
ides in this form retain the full biological activity of the
elected phage or support-linked peptide. This may be
ue to similarity between the MAP dendrimeric forms
nd phage or solid phase-linked peptides. Phage and
olid phase-linked peptide libraries display peptides
ith the same orientation, from C-terminal to N-ter-
inal, as in MAPs, where the peptide sequences are
inked to the lysine core by their C-terminal (Figure 7).
oreover, the MAP molecule contains many peptide
opies, allowing multivalent binding and increased
inding efficiency, as for phage and solid phase-
inked peptides.
This suggests that synthesis of peptides in MAP form
an be a general strategy for maintaining biological ac-
ivity in the transition from solid-phase or phage selec-
ion of peptide sequences to production of peptides
Review
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tures
See text for details.pared to that of macromolecules like antibodies, en-
Figure 7. Schematic Representation of the Similarity of MAP to
Phage Displayed (A) and Membrane Bound (B) Peptides
See text for details.as soluble compounds. Moreover, MAPs are stable to
peptidases and proteases, and this can be of primary
importance in the development of new peptide drugs.
The use of peptides as drugs has not only been lim-
ited by their natural susceptibility to proteolytic degra-
dation, but also by the general difficulty of delivery in-
side cells. Peptides generally have a limited ability to
cross the plasma membrane, with the notable excep-
tion of antimicrobial peptides and cell-penetrating pep-
tides (CPP) [98], like Tat, penetratin, and VP22. Most
CPP identified so far are cationic sequences, derived
from natural viral or animal sequences, or identified by
chemical synthesis. They share the ability to cross cell
membranes and work as carriers, transporting pep-
tides, proteins, and even larger molecules or particles
inside cells. CPP have largely been used to deliver pep-
tides to intracellular targets [98]. The drawback of
irreversible conjugation of peptides to CPP is the pos-
sible intracellular mislocalization of peptides, driven by
the CPP sequence itself. This was recently solved in
an elegant manner by synthesis of intracellular acting
synthetic peptides, reversibly conjugated to Tat [99].
Future Perspectives
Peptides are versatile molecules with enormous poten-
tial for therapeutic applications. Their small size, com-hances their tissue permeability. They are readily pre-
pared by chemical synthesis and are easily modified
and linked to different functional moieties.
Molecular diversity can be generated by biological or
synthetic combinatorial peptide libraries combined with
rational molecular design, to select lead bioactive pep-
tides for a variety of biological targets. The combination
of these two approaches can take place at different steps
in the selection process and the preponderance of ratio-
nal or irrational depends on the availability of structural-
functional information on the peptide and its target.
The main limit to the use of peptides as drugs seems
to be their short half-life due to proteolysis.
Several strategies can be used to maintain the pep-
tide bioactivity in the transition from peptide selection
by combinatorial libraries to use in vivo; however, the
biological activity of second generation compounds
may be profoundly altered. The synthesis of selected
bioactive peptides in MAP dendrimeric form can be an
alternative method of conserving biological activity by
inducing resistance to degradation by proteases and
peptidases.
MAPs composed only of natural amino acids but with
a longer half-life than natural peptides have major ap-
plications as therapeutic drugs. An important possible
application of protease-resistant MAPs may be in tu-
mor therapy and diagnosis. Endogenous regulatory
peptides, the receptors of which are overexpressed in
different types of cancer, can be prepared and used in
MAP form as tumor receptor-targeting agents.
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